[Note: to read the full text of this article at no charge, click HERE. As an example, the PatientsLikeMe.com database includes data supplied by more than 19,000 ME/CFS and fibromyalgia patients. To see details, click HERE.]
Background: Evaluating a new use for an existing drug can be expensive and time consuming. Providers and patients must all too often rely upon their own individual-level experience to inform clinical practice, which generates only anecdotal and unstructured data.
While academic-led clinical trials are occasionally conducted to test off-label uses of drugs with expired patents, this is relatively rare.
In this work, we explored how a patient-centered online research platform could supplement traditional trials to create a richer understanding of medical products postmarket by efficiently aggregating structured patient-reported data.
PatientsLikeMe is a tool for patients, researchers, and caregivers (currently 82,000 members across 11 condition-based communities) that helps users make treatment decisions, manage symptoms, and improve outcomes.
Members enter demographic information, longitudinal treatment, symptoms, outcome data, and treatment evaluations. These are reflected back as longitudinal health profiles and aggregated reports. Over the last 3 years, patients have entered treatment histories and evaluations on thousands of medical products. These data may aid in evaluating the effectiveness and safety of some treatments more efficiently and over a longer period of time course than is feasible through traditional trials.
Objective: The objective of our study was to examine the illustrative cases of amitriptyline and modafinil – drugs commonly used off-label.
Methods: We analyzed patient-reported treatment histories and drug evaluations for each drug, examining prevalence, treatment purpose, and evaluations of effectiveness, side effects, and burden.
Results: There were 1,948 treatment histories for modafinil and 1,394 treatment reports for amitriptyline reported across five PatientsLikeMe communities (multiple sclerosis, Parkinson's disease, mood conditions, fibromyalgia/chronic fatigue syndrome, and amyotrophic lateral sclerosis).
In these reports, the majority of members reported taking the drug for off-label uses.
Only 34 of the 1,755 (1%) reporting purpose used modafinil for an approved purpose (narcolepsy or sleep apnea).
Only 104 out of 1,197 members (9%) reported taking amitriptyline for its approved indication, depression.
Members taking amitriptyline for off-label purposes rated the drug as more effective than those who were taking it for its approved indication.
While dry mouth is a commonly reported side effect of amitriptyline for most patients, 88 of 220 (40%) of people with amyotrophic lateral sclerosis on the drug reported taking advantage of this side effect to treat their symptom of excess saliva.
Conclusions: Patient-reported outcomes, like those entered within PatientsLikeMe, offer a unique real-time approach to understand utilization and performance of treatments across many conditions.
These patient-reported data can provide a new source of evidence about secondary uses and potentially identify targets for treatments to be studied systematically in traditional efficacy trials.
Source: Journal of Medical Internet Research, Jan 21, 2011. PMID: 21252034, by Frost J, Okun S, Vaughan T, Heywood J, Wicks P. VU Amsterdam, Amsterdam, Netherlands; PatientsLikeMe Inc., Cambridge, Massachusetts, USA. [Email: email@example.com]